Atlas Trials

Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

Clinical trial NCT06549335 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06549335
Sponsor
Ruijin Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Follicular Lymphoma
Start date
2024-12-01
Primary completion
2026-12-01
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.